| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 1999;34:782-789.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Alton Ochsner Medical Foundation, New Orleans, La.
Correspondence to Edward D. Frohlich, MD, Alton Ochsner Distinguished Scientist, Vice President for Academic Affairs, Alton Ochsner Medical Foundation, 1516 Jefferson Hwy, New Orleans, LA 70121.
AbstractIn this report, some of the underlying pathophysiological alterations associated with the independent risk from hypertensive heart disease and left ventricular hypertrophy are discussed. Emphasized are the classically described coronary hemodynamic alterations of decreased coronary blood flow and flow reserve with increased coronary vascular resistance and minimal coronary resistance; more recent concepts of endothelial dysfunction are emphasized. Additionally, increased collagen deposition within the ventricular walls and perivascularly participates importantly. These changes are exacerbated by the aging process and perhaps by increased dietary salt intake. Consequences of these functional and structural changes include further endothelial dysfunction, impairment of coronary hemodynamics, and ventricular contractile function (diastolic as well as systolic). The clinical consequences of these alterations are angina pectoris (with or without atherosclerosis), myocardial infarction, cardiac failure, lethal dysrhythmias, and sudden cardiac death. Thus, not all that is clinically recognized as "left ventricular hypertrophy" is true myocytic hypertrophy with structural remodeling; other important comorbid changes occur that directly affect risk, including ventricular fibrosis, impaired coronary hemodynamics, and endothelial dysfunction.
Key Words: left ventricular hypertrophy coronary heart disease coronary hemodynamics fibrosis sudden death risk
This article has been cited by other articles:
![]() |
C. Bolte, G. Newman, and J. E. J. Schultz Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac {kappa}-opioid receptor stimulation Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H967 - H975. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Muiesan, M. Salvetti, A. Paini, C. Agabiti-Rosei, C. Monteduro, G. Galbassini, E. Belotti, C. Aggiusti, D. Rizzoni, M. Castellano, et al. Inappropriate Left Ventricular Mass in Patients With Primary Aldosteronism Hypertension, September 1, 2008; 52(3): 529 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Rajab, E Stearns, and S Baithun Autopsy pathology of cocaine users from the Eastern district of London: a retrospective cohort study J. Clin. Pathol., July 1, 2008; 61(7): 848 - 850. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Varagic, E. D. Frohlich, D. Susic, J. Ahn, L. Matavelli, B. Lopez, and J. Diez AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H853 - H858. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Agabiti-Rosei, M. L. Muiesan, and M. Salvetti Review: New approaches to the assessment of left ventricular hypertrophy Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 119 - 128. [Abstract] [PDF] |
||||
![]() |
E. D. Frohlich The Salt Conundrum: A Hypothesis Hypertension, July 1, 2007; 50(1): 161 - 166. [Full Text] [PDF] |
||||
![]() |
M. L. Muiesan, M. Salvetti, A. Paini, C. Monteduro, G. Galbassini, B. Bonzi, P. Poisa, E. Belotti, C. Agabiti Rosei, D. Rizzoni, et al. Inappropriate Left Ventricular Mass Changes During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive Patients Hypertension, May 1, 2007; 49(5): 1077 - 1083. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy Cardiovasc Res, January 15, 2007; 73(2): 257 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Pfeffer and E. D. Frohlich Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2021 - H2025. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Mancia, F. Scopelliti, and G. Grassi Hypertension and the Heart. Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 198 - 202. [Abstract] [PDF] |
||||
![]() |
M. C. C. Borges, R. C.R. Colombo, J. G. F. Goncalves, J. d. O. Ferreira, and K. G. Franchini Longitudinal Mitral Annulus Velocities Are Reduced in Hypertensive Subjects With or Without Left Ventricle Hypertrophy Hypertension, May 1, 2006; 47(5): 854 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Agabiti-Rosei, M. L. Muiesan, and M. Salvetti Evaluation of Subclinical Target Organ Damage for Risk Assessment and Treatment in the Hypertensive Patients: Left Ventricular Hypertrophy J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S104 - S108. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Meneton, X. Jeunemaitre, H. E. de Wardener, and G. A. Macgregor Links Between Dietary Salt Intake, Renal Salt Handling, Blood Pressure, and Cardiovascular Diseases Physiol Rev, April 1, 2005; 85(2): 679 - 715. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ahn, J. Varagic, M. Slama, D. Susic, and E. D. Frohlich Cardiac structural and functional responses to salt loading in SHR Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H767 - H772. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Albert, J. Torres, R. J. Glynn, and P. M Ridker Perspective on Selected Issues in Cardiovascular Disease Research With a Focus on Black Americans Circulation, July 13, 2004; 110(2): e7 - e12. [Full Text] [PDF] |
||||
![]() |
E. D. Frohlich Left ventricular hypertrophy: a "factor of risk": Mass is reversible, but is the risk? J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2216 - 2218. [Full Text] [PDF] |
||||
![]() |
M. L. Muiesan, M. Salvetti, C. Monteduro, B. Bonzi, A. Paini, S. Viola, P. Poisa, D. Rizzoni, M. Castellano, and E. Agabiti-Rosei Left Ventricular Concentric Geometry During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive Patients Hypertension, April 1, 2004; 43(4): 731 - 738. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kozakova, G. de Simone, C. Morizzo, and C. Palombo Coronary Vasodilator Capacity and Hypertension-Induced Increase in Left Ventricular Mass Hypertension, February 1, 2003; 41(2): 224 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
G MacGregor and H. de Wardener Commentary: Salt, blood pressure and health Int. J. Epidemiol., April 1, 2002; 31(2): 320 - 327. [Full Text] [PDF] |
||||
![]() |
G. Grassi, G. Seravalle, G. Bertinieri, M. L. Stella, C. Turri, and G. Mancia Sympathetic Response to Ventricular Extrasystolic Beats in Hypertension and Heart Failure Hypertension, April 1, 2002; 39(4): 886 - 891. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Frohlich Local Hemodynamic Changes in Hypertension: Insights for Therapeutic Preservation of Target Organs Hypertension, December 1, 2001; 38(6): 1388 - 1394. [Abstract] [Full Text] [PDF] |
||||
![]() |
K E Berkin and S G Ball HYPERTENSION: Essential hypertension: the heart and hypertension Heart, October 1, 2001; 86(4): 467 - 475. [Full Text] [PDF] |
||||
![]() |
J. P. Bell, S. I. Mosfer, D. Lang, F. Donaldson, and M. J. Lewis Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1704 - H1710. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Khan, C. D. Lynch, D. C. Sane, M. C. Willingham, and W. E. Sonntag Growth Hormone Increases Regional Coronary Blood Flow and Capillary Density in Aged Rats J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2001; 56(8): B364 - 371. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Varagic, D. Susic, and E. D. Frohlich Coronary Hemodynamic and Ventricular Responses to Angiotensin Type 1 Receptor Inhibition in SHR : Interaction With Angiotensin Type 2 Receptors Hypertension, June 1, 2001; 37(6): 1399 - 1403. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Varagic, D. Susic, and E. D. Frohlich Cardiovasc Pharmacol Therapeut 6(1):57-63, 2001 Low-Dose ACE with Alphaor Beta-Adrenergic Receptor Inhibitors Have Beneficial SHR Cardiovascular Effects Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 57 - 63. [Abstract] [PDF] |
||||
![]() |
E. D Frohlich Review: Promise of prevention and reversal of target organ involvement in hypertension Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S4 - S9. [PDF] |
||||
![]() |
R. Zeltner, C. Delles, M. Schneider, W. Siffert, and R. E. Schmieder G-Protein {beta}3 Subunit Gene (GNB3) 825T Allele Is Associated With Enhanced Renal Perfusion in Early Hypertension Hypertension, March 1, 2001; 37(3): 882 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Susic, J. Varagic, and E. D. Frohlich Abnormal Renal Vascular Responses to Dipyridamole-Induced Vasodilation in Spontaneously Hypertensive Rats Hypertension, March 1, 2001; 37(3): 894 - 897. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Perry, E. D. Freis, and E. D. Frohlich Department of Veterans Affairs Hypertension Meeting : A Proposal for Improved Care Hypertension, April 1, 2000; 35(4): 853 - 857. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dodic, C. Samuel, K. Moritz, E. M. Wintour, J. Morgan, L. Grigg, and J. Wong Impaired Cardiac Functional Reserve and Left Ventricular Hypertrophy in Adult Sheep After Prenatal Dexamethasone Exposure Circ. Res., September 28, 2001; 89(7): 623 - 629. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |